Providing a Clinical Update of an EGFR Targeted ADC MRG003

Time: 11:45 am
day: Track C - Day 1 - AM

Details:

  • Review the ADC landscape in China
  • Investigate potent anti-tumour activity in preclinical studies
  • Demonstrate manageable safety and promising efficacy in early phase clinical studies

Speakers: